<DOC>
	<DOCNO>NCT00652431</DOCNO>
	<brief_summary>This single-center , randomize , open-label , 3-period , 3-treatment multiple-dose crossover study design assess interaction VYTORIN® ( Ezetimibe Simvastatin ) NIASPAN® ( Niacin Extended-Release Tablets ) healthy subject . Treatment span 7 day</brief_summary>
	<brief_title>Assessment Interaction Between Vytorin Niaspan Healthy Subjects ( P04955AM2 )</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Ezetimibe , Simvastatin Drug Combination</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>The subject must meet ALL criterion list entry : Subjects must willing give write informed consent able adhere dose visit schedule . Subjects either sex race age 18 55 year , inclusive , Body Mass Index ( BMI ) 19 32 , inclusive . BMI = weight ( kg ) /height ( m^2 ) . Subjects ' clinical laboratory test ( CBC , blood chemistry , urinalysis ) must within normal limit clinically acceptable investigator/sponsor . Subject 's liver function test result ( AST , ALT , GGT ) must elevate normal limit Screening Day1 . Subjects ' CPK test result must elevate 1.25 time upper limit normal , Screening Day 1 . Subjects must free clinically significant disease would interfere study evaluation . Screening ECG conduction interval must within gender specific normal range ( QTc males &lt; =430 msec female &lt; =450 msec ) . Vital sign measurement ( take ~3 minute seat position ) must within follow range : oral body temperature 35.0°C 37.5°C systolic blood pressure , 90 140 mm Hg diastolic blood pressure , 45 90 mm Hg pulse rate , 40 100 bpm Female subject childbearing potential must negative serum pregnancy test ( betahCG ) Screening negative urine pregnancy test upon admission study center . Women childbearing potential must agree use medically accept method contraception prior screening , receive protocolspecified medication , 30 day stop medication . Acceptable method contraception include : Condoms ( male female ) spermicide , Diaphragm cervical cap spermicide Medically prescribe IUD spermicide , Surgical sterilization ( eg . hysterectomy tubal ligation ) . Vasectomy partner consider single barrier one additional contraceptive method list must use . Females currently sexually active must agree consent use one abovementioned method become sexually active participate study . Female subject must surgically sterilize ( eg , document hysterectomy tubal ligation ) postmenopausal . ( Defined 12 month menses estradiol level &lt; 30 pg/mL . ) Men must agree use medically accept method contraception prior Screening , receive protocolspecified medication , 30 day stop medication . The subject exclude entry ANY criterion list meet : Female subject pregnant , intend become pregnant ( within 3 month end study ) , breastfeed . Subjects , opinion investigator , able participate optimally study . Any surgical medical condition might significantly alter absorption , distribution , metabolism excretion drug . The investigator guide evidence follow discuss sponsor prior enrollment trial : history presence inflammatory bowel disease , ulcer , gastrointestinal rectal bleeding ; history major gastrointestinal tract surgery gastrectomy , gastroenterostomy , bowel resection ; history pancreatic injury pancreatitis ; history presence liver disease liver injury ; history presence impair renal function indicate abnormal creatinine , urinary albumin , BUN/urea clinical significant urinary cellular constituent ( eg , cast ) ; history urinary obstruction difficulty void . Subject history infectious disease within 4 week prior drug administration . Subjects positive hepatitis B surface antigen , hepatitis C antibodies HIV . Subjects positive screen drug high potential abuse . Subjects history mental instability treat mood disorder . Subjects history alcohol drug abuse past 2 year . Subjects donate blood past 60 day . Subjects previously receive demonstrated intolerance NIASPAN® ( niacin extendedrelease tablet ) , VYTORIN® ( ezetimibe/simvastatin ) , ZETIA® ( ezetimibe ) , ZOCOR® ( simvastatin ) product contain niacin/nicotinic acid . Subjects currently participate another clinical study participate clinical study within 30 day . Subjects part study staff personnel family member study staff personnel . Subjects demonstrate allergic reaction ( eg , food , drug , atopic reaction asthmatic episode ) . Subjects smoke 10 cigarette equivalent tobacco use per day . Subjects receive treatment list Table 2 protocol P04955 ( Doc ID : 3498819 ) recently indicate washout period prior Baseline period . Subjects receive vaccination ( ) within 30 day prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>